Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
682.6(c) 685.6(c) 692.6(c) 705.2(c) 708.4 Last
168 552 132 729 143 583 198 678 43 569 Volume
-0.50% +0.44% +1.02% +1.82% +0.45% Change
More quotes
Estimated financial data (e)
Sales 2021 5 116 M 5 644 M 5 644 M
Net income 2021 789 M 870 M 870 M
Net cash position 2021 51,1 M 56,4 M 56,4 M
P/E ratio 2021 67,1x
Yield 2021 0,44%
Sales 2022 5 763 M 6 358 M 6 358 M
Net income 2022 1 035 M 1 142 M 1 142 M
Net cash position 2022 83,2 M 91,7 M 91,7 M
P/E ratio 2022 50,1x
Yield 2022 0,47%
Capitalization 52 384 M 57 809 M 57 790 M
EV / Sales 2021 10,2x
EV / Sales 2022 9,08x
Nbr of Employees 14 405
Free-Float 99,6%
More Financials
Company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. 
More about the company
Ratings of Lonza Group AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about LONZA GROUP AG
07/29LONZA : Committee Member Offloads Shares for $1 Million
MT
07/28LONZA : Credit Suisse Lifts Price Target on Lonza Group, Maintains Outperform Re..
MT
07/28MODERNA : Expects COVID-19 Vaccine Supply Issues To Persist Outside US
MT
07/27Moderna says COVID-19 vaccine supply outside United States to slow down
RE
07/27Manufacturing Woes Plague Shipment of Moderna COVID-19 Jab to South Korea
MT
07/27Moderna says COVID-19 vaccine supply outside United States to slow down
RE
07/26LONZA : Equita SIM SpA Lifts Price Target on Lonza Group, Maintains Buy Recommen..
MT
07/26ANALYST RECOMMENDATIONS : Casey's, D.R. Horton, Microsoft, Unilever, Veoneer...
07/23European Stocks Rally After Dovish ECB Comments, Surge in PMI Services and Ou..
MT
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23LONZA : Contemplates Acquisitions to Boost Booming Vaccine Manufacturing Busines..
MT
07/23LONZA : Half-Year Alternative Performance Measures Report
PU
07/23Vaccine business helps Lonza lift 2021 sales outlook
RE
07/23LONZA : H1 Profit Falls as Environmental Provisions Bite Into Revenue Jump
MT
07/23LONZA : Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3..
PU
More news
News in other languages on LONZA GROUP AG
03:32aMADRID STOCK EXCHANGE : Recta final antes de la pausa de agosto
02:04aAVIS D'ANALYSTES DU JOUR : L'Oréal, Renault, Schneider Electric, Valeo, Atos, Bu..
01:05aSTOCK MARKET PARIS : Dernière ligne droite avant la coupure aoûtienne
07/30Aktien Schweiz gehen etwas fester ins Wochenende
07/30L'EMA approuve l'augmentation de la production du vaccin Moderna aux Etats-Un..
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 705,20 CHF
Average target price 732,83 CHF
Spread / Average Target 3,92%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG23.98%57 809
MODERNA, INC.238.47%141 980
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907
CUREVAC N.V.-39.24%21 497